TargetMol

Procarbazine free base

Product Code:
 
TAR-T1488L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1488L-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1488L-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1488L-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Procarbazine is an antineoplastic chemotherapy drug for the treatment of Hodgkin's lymphoma and certain brain cancers. The drug is metabolized and activated in the liver. It also inhibits MAO thus increasing the effects of sympathomimetics, TCAs, and tyramine.
CAS:
671-16-9
Formula:
C12H19N3O
Molecular Weight:
221.304
Purity:
0.98
SMILES:
CNNCc1ccc(cc1)C(=O)NC(C)C

References

1. Revollo J, Bhalli JA, Tebbe C, Noteboom J, Thomas D, McKinzie P, Felton N, Pearce MG, Dobrovolsky VN. Spectrum of Pig-a mutations in T lymphocytes of rats treated with procarbazine. Mutagenesis. 2017 Dec 8. doi: 10.1093/mutage/gex032. [Epub ahead of print] PubMed PMID: 29237063. 2. Schiff D. Low-grade Gliomas. Continuum (Minneap Minn). 2017 Dec;23(6, Neuro-oncology):1564-1579. doi: 10.1212/CON.0000000000000537. PubMed PMID: 29200111. 3. Nayak L, Reardon DA. High-grade Gliomas. Continuum (Minneap Minn). 2017 Dec;23(6, Neuro-oncology):1548-1563. doi: 10.1212/CON.0000000000000554. PubMed PMID: 29200110. 4. Kobe C, Dietlein M, Hellwig D. PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma. Semin Nucl Med. 2018 Jan;48(1):28-36. doi: 10.1053/j.semnuclmed.2017.09.003. Epub 2017 Sep 19. Review. PubMed PMID: 29195615.